Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Abivax SA American Depositary Shares(ABVX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABVX
10/08/2026: ABVX (3-star) is currently NOT-A-BUY. Pass it for now.
Abivax is a clinical-stage biotechnology company developing small molecule therapeutics to modulate the immune system for inflammatory diseases. Its primary value proposition centers on obefazimod, an oral candidate targeting ulcerative colitis, which offers a potential alternative to injectable biologics. The company's strengths lie in its specialized RNA-modulation platform and promising early clinical data. However, as a pre-revenue firm, Abivax faces substantial risks, including a heavy reliance on a single asset and the need for ongoing capital to fund expensive late-stage trials. It best suits risk-tolerant investors who monitor clinical trial progress and the potential for strategic partnerships with larger industry players.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a speculative growth play based entirely on the success of a single lead asset in clinical trials. |
| Momentum investor | Mixed fit | Momentum is highly sensitive to binary news events regarding clinical trial results. |
| Value investor | Weak fit | The company has no revenue or earnings, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company is a clinical-stage biotech and does not pay dividends. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks are inherently high-risk assets. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price reacts sharply to clinical and financing updates. |
| Valuation risk | High | Valuation is based on long-term clinical expectations rather than current financial performance. |
| Competition risk (inflammatory disease market) | High | Competing with major pharmaceutical players requires superior clinical outcomes. |
| Business quality | Medium | The company relies on a singular proprietary platform, which is scientifically strong but commercially untested. |
| Dividend income | Low / none | There is no income generation for investors. |
| Execution risk | High | Successfully managing large-scale global trials and regulatory filings is a significant operational challenge. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 208.84% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.59B USD | Price to earnings Ratio - | 1Y Target Price 164 |
Price to earnings Ratio - | 1Y Target Price 164 | ||
Volume (30-day avg) 1.3M shares | Beta -0.23 | 52 Weeks Range 69.81 - 148.83 | Updated Date 10/07/2026 |
52 Weeks Range 69.81 - 148.83 | Updated Date 10/07/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.08 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research and Development | Advancement of the lead drug candidate obefazimod. | The company is currently spending money to develop a drug and does not yet have products on the market to generate sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7.90B | Price to Sales(TTM) 1626.71 |
Enterprise Value 7.90B | Price to Sales(TTM) 1626.71 | ||
Enterprise Value to Revenue 157.63 | Enterprise Value to EBITDA -12.66 | Shares Outstanding 87.27M | Shares Floating 69.03M |
Shares Outstanding 87.27M | Shares Floating 69.03M | ||
Percent Insiders - | Percent Institutions 72.27 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.